Assembly Biosciences (NASDAQ:ASMB) Upgraded by UBS Group to “Strong-Buy” Rating

Assembly Biosciences (NASDAQ:ASMB) was upgraded by stock analysts at UBS Group to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Several other research firms have also recently commented on ASMB. Guggenheim restated a “buy” rating and set a $43.00 target price on shares of Assembly Biosciences in a research report on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Mizuho set a $53.00 price target on Assembly Biosciences in a research report on Tuesday. Wall Street Zen lowered Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Zacks Research raised shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $45.60.

Assembly Biosciences Trading Up 4.6%

Shares of NASDAQ:ASMB opened at $35.18 on Tuesday. The company has a 50 day moving average of $28.55 and a 200 day moving average of $28.00. The stock has a market cap of $716.26 million, a P/E ratio of 34.49 and a beta of 1.12. Assembly Biosciences has a 12 month low of $20.23 and a 12 month high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.52. The firm had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. On average, equities analysts forecast that Assembly Biosciences will post 2.28 earnings per share for the current fiscal year.

Institutional Trading of Assembly Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. purchased a new position in shares of Assembly Biosciences during the third quarter worth approximately $26,122,000. Janus Henderson Group PLC boosted its stake in shares of Assembly Biosciences by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock valued at $23,479,000 after purchasing an additional 11,384 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new position in shares of Assembly Biosciences during the 4th quarter valued at $22,625,000. Vanguard Group Inc. raised its position in Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after purchasing an additional 248,287 shares during the period. Finally, Seven Fleet Capital Management LP raised its position in Assembly Biosciences by 671.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock worth $11,903,000 after purchasing an additional 377,000 shares during the period. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.